Safety and immunogenicity of VAQTA® in children 12-to-23 months of age with and without administration of other US pediatric vaccines

Safety and immunogenicity of VAQTA® in children 12-to-23 months of age with and without administration of other US pediatric vaccines

Safety and immunogenicity data from 5 clinical trials conducted in the US in children 12-to-23 months old where HAVi was administered alone or concomitantly with other pediatric vaccines (M-M-R®II, Varivax®, TRIPEDIA®, Prevnar®, ProQuad®, PedvaxHIB®, and INFANRIX®) were combined. Among 4,374 partici...

Full description

Bibliographic Details
Main Authors: Maria Petrecz, Camilo J. Acosta, Stephanie O. Klopfer, Barbara J. Kuter, Michelle G. Goveia, Jon E. Stek, Florian P. Schödel, Andrew W. Lee
Format: Article
Language:English
Published: Taylor & Francis Group 2019-02-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
safety
immunogenicity
hepatitis a vaccine
integrated analyses
Online Access:http://dx.doi.org/10.1080/21645515.2018.1530934

Similar Items

Similar Items